Offering adjunct therapies to GLP-1RA use in advanced stages of dementia, such as cholinesterase inhibitors and monoclonal antibodies, raises the possibility of synergistic effects, such as neuroinflammation and insulin signalling modulation potentiating the effects of amyloid clearance.4 Here, INS is linked to dementia.